BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27227942)

  • 1. Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.
    Al-Muqbel KM; Yaghan RJ
    Medicine (Baltimore); 2016 May; 95(21):e3753. PubMed ID: 27227942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
    Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
    Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
    Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
    Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
    Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
    Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
    PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.
    Nakai T; Okuyama C; Kubota T; Yamada K; Ushijima Y; Taniike K; Suzuki T; Nishimura T
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1253-8. PubMed ID: 16133397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
    Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
    Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Bone Lesions with
    van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
    J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis.
    Liu NB; Zhu L; Li MH; Sun XR; Hu M; Huo ZW; Xu WG; Yu JM
    Asian Pac J Cancer Prev; 2013; 14(6):3647-52. PubMed ID: 23886160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
    Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
    Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
    Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
    Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
    Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
    Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.
    Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J
    BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.
    Min JW; Um SW; Yim JJ; Yoo CG; Han SK; Shim YS; Kim YW
    J Korean Med Sci; 2009 Apr; 24(2):275-80. PubMed ID: 19399270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.